CAR-T Meeting 2023 | Unmet needs in second-line DLBCL and challenges in this space

So we know that for many patients who relapse after their first line treatment that our current standard of care, which is if patients are fit, taking them to high dose therapy and an auto, that many patients don’t do very well with this approach. A lot of people aren’t selected to proceed with this because they’re not fit enough. A BEAM autographt is one of the most toxic treatments that we give to a patient. And then those patients that are fit enough to proceed, there are a percentage of them that don’t achieve a good enough response to that second line high dose therapy. And so again, we would not go and give them an autologous stem cell transplant.

The other problem is is that we have to collect stem cells, adequate stem cells from them, and for some patients we are not successful in doing this. So our current second-line standard of care doesn’t suit many patients. And we have to think about what we offer for our auto-ineligible patients, so those patients that aren’t fit, and again, standard chemoimmunotherapy has really disappointing responses.